Story

European Stocks Advance as Tech Rally and Oil Price Retreat Boost Sentiment

ENTHMSVIIDZHZH-TWJAKOHI
Sep 21, 20261 min read
European Stocks Advance as Tech Rally and Oil Price Retreat Boost Sentiment

Summary

The pan-European STOXX 600 gained on Monday, led by a roughly 2% jump in technology stocks, while a fourth consecutive session of declines in crude oil prices eased inflation concerns and lifted travel shares.

Text size
Background

European equities advanced on Monday morning, with the benchmark STOXX 600 index rising as a rally in technology shares and a continued retreat in oil prices bolstered investor sentiment.

Market Snapshot

The pan-European STOXX 600 was up 0.56% to 638.98 points by 0710 GMT, rebounding from a 0.6% dip the prior week, according to Reuters data. Major regional bourses also traded in positive territory, with Germany's DAX index climbing 0.76%.

Investors were also digesting macroeconomic and political news, including data from Sweden showing an easing of long-term inflation expectations in September and the results of state elections in northeastern Germany.

Sector Divergence: Tech Gains as Energy Falls

The technology sector was the morning's top performer, advancing roughly 2%. The rally was driven by strength in semiconductor-related stocks, including French materials manufacturer Soitec and German equipment provider Aixtron.

Sample IUX Markets – In-articleAd

Conversely, the energy sector slipped 0.62%, tracking a fourth consecutive session of declines in crude oil prices. The drop in oil provided a tailwind for travel and leisure stocks, which rose 0.86% on the prospect of lower fuel costs for airlines.

Key Stock Movements

Several individual stocks saw significant price action in early trading:

  • Nordnet: Shares in the Swedish digital bank jumped 4.6% after the company announced a share buyback program.
  • Ipsen: The French biotech firm was a notable decliner, with its stock falling more than 6%.
  • AstraZeneca: The pharmaceutical giant's shares edged down 0.32%, despite news that its cancer treatment Enhertu was recommended for approval in the European Union for a new use case.

Read next

More on Stocks
Back to latest news

LATEST